Form 4: Guardant Health Director Roberto Mignone Receives Equity Compensation Grants

Guardant Health, Inc. Director Roberto Mignone was granted 6,833 stock options and 4,203 restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Roberto Mignone, a Director at Guardant Health, Inc. (GH), was granted derivative securities on June 18, 2025.
• He received 6,833 stock options with an exercise price of $50.57 per share.
• He also received 4,203 Restricted Stock Units (RSUs).
• Both the stock options and RSUs are scheduled to vest in full on the one-year anniversary of the grant date (June 18, 2026) or the date of the next annual stockholders meeting, whichever is earlier.
• The granted stock options have an expiration date of June 18, 2035.
• Following these transactions, Mr. Mignone directly beneficially owns 6,833 stock options and 4,203 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The grant of equity compensation to a director is generally a neutral to slightly positive event, indicating ongoing alignment of interests and retention efforts, but does not reflect operational performance or significant strategic shifts.

Positives

• The grant of equity compensation aligns the director's financial interests with the long-term performance and shareholder value of Guardant Health, Inc.
• The vesting schedule for both the stock options and Restricted Stock Units serves as an incentive for the director's continued retention and commitment to the company.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider equity compensation, common across publicly traded companies in the healthcare and biotechnology sectors, aimed at aligning executive and director incentives with company performance and long-term strategic goals.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a standard practice for executive and director compensation in the biotechnology and healthcare industry.
• This compensation structure is comparable to those seen at other publicly traded companies in the sector, such as Illumina, Inc. (ILMN) or Exact Sciences Corp. (EXAS), which frequently utilize equity awards to attract and retain talent and align interests with shareholders.
• The specific amounts and vesting schedules are typical for non-employee director compensation packages, reflecting a balance between immediate incentive and long-term commitment.

Related Party Transactions

• Director Roberto Mignone, a related party, was granted 6,833 stock options and 4,203 Restricted Stock Units by Guardant Health, Inc. as part of his compensation.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value, potentially leading to better long-term decision-making. However, they also represent potential future dilution if options are exercised and RSUs convert to shares.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The granted stock options and Restricted Stock Units will vest in full on June 18, 2026, or the date of the next annual stockholders meeting, whichever is earlier.
• The stock options will expire on June 18, 2035.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Roberto Mignone